Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 567 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Prostate Carcinoma Clear all
Recruiting Phase 2 Interventional

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

NCT04700332
View directory record Official record
Conditions
Prostate Cancer
Interventions
DCFPyL PET/CT
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer

NCT00032006
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carboplatin, docetaxel, estramustine phosphate sodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT00726596
View directory record Official record
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

NCT00670046
View directory record Official record
Conditions
Prostate Cancer
Interventions
valproic acid, standard of care follow-up
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions
[18F]CTT1057, [68Ga]Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00015977
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, recombinant interleukin-12
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 4, 2026, 4:03 PM EDT
Withdrawn Not applicable Interventional

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

NCT02169063
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
carbon-11 acetate, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional Results available

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00524589
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, protein expression analysis, laboratory biomarker analysis
Dietary Supplement · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005820
View directory record Official record
Conditions
Prostate Cancer
Interventions
nitrocamptothecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00040755
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

NCT05605522
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions
[225]-FPI-2059, [111In]-FPI-2058
Drug
Lead sponsor
3B Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Duarte, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Cilengitide in Treating Patients With Metastatic Prostate Cancer

NCT00103337
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
cilengitide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 4, 2026, 4:03 PM EDT
Recruiting No phase listed Observational

MRI/Ultrasound Fusion Guided Prostate Cryotherapy

NCT02381990
View directory record Official record
Conditions
Neoplasms Prostate, Cancer of the Prostate
Interventions
FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY
Procedure
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
55 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

NCT00005067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
motexafin lutetium, photodynamic therapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

NCT00002881
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Stage IV Prostate Cancer

NCT00003781
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
docetaxel, pain therapy, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Sep 4, 2026, 4:03 PM EDT
Active, not recruiting Phase 2 Interventional

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

NCT05496959
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970
View directory record Official record
Conditions
Prostate Cancer
Interventions
celecoxib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 4, 2026, 4:03 PM EDT